Fosun Pharma: The new drug of its holding subsidiary completes the clinical phase I trial
Fosun Pharma Announces that the Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection Developed by Fuhong Hanlin, a Controlled Subsidiary of the Company, completed the Phase I clinical trial and recently launched the new drug for the treatment of metastatic colorectal cancer indications. Phase III trial. The new drug is a monoclonal antibody biosimilar drug independently developed by the company. It is mainly used for the indication of metastatic colorectal cancer, indications for non-small cell lung cancer, wet age-related macular degeneration and indications for diabetic retinopathy.
Wo Jing Technology: Introducing Warrants Jingzhou Huihe to Resume Trading in Tomorrow
Sujing Technology Announced that the company’s controlling shareholder, the controlling shareholder Chen Bolin, and some shareholders planned to introduce new partners that meet the development strategy of the listed company. New progress has been made: Chen Bolin and 6 other shareholders plan to share 12% of the company’s shares, that is, 5387 shares. It was transferred to Jingzhou Huihe Equity Investment Partnership (Limited Partnership) at a price of RMB 12.2 per share for a total transfer price of RMB 657 million. After the transaction, the controlling shareholder and the actual controller of the company will remain unchanged, and Jingzhou Huihe will become the company's second largest shareholder. The company's shares resume trading on the 16th.
Yuanda Smart: Received an invitation letter for overseas PPP project cooperation
Yuanda Smart Announcement, the company received the "Power Building Project Cooperation Invitation Letter" issued by the ARSEL agency of the Republic of Cameroon. According to the proposal and quotation provided by the company for the construction of the electric power building project in PPP mode, the company was invited to dispatch a capable operation team to Yawen. Get the project site to work and meet in order to complete the program. The company’s offer for the entire power building project is US$160 million and the project operating cycle is 22 years.
Longji shares: plans to 1.2 billion investment in the construction of Chuxiong Monocrystalline Silicon Phase II project
Longji announced that the company signed an investment agreement with the Yunnan Chuxiong Yi Autonomous Prefecture Government in December 2016 and reached an agreement on the company’s investment and construction of a 10GW monocrystalline wafer construction project (phase 1 project). The project has now been partially put into production. According to the needs of strategic development, the company signed a project investment agreement with related parties on April 15, 2018, and reached an agreement on the new phase of the first phase of the project to build a 10GW single crystal silicon wafer project (phase 2 project). Investment is expected to reach 1.2 billion yuan.
Qing Song shares: 2017 net profit increased by 189% year-on-year
Qing Song (300132) disclosed its annual report on the evening of April 15. The company achieved operating revenue of 811 million yuan in 2017, an increase of 45.56% year-on-year; net profit of 94.746 million yuan, a year-on-year increase of 189.44%; earnings per share of 0.25 yuan. The company plans to distribute a dividend of RMB 0.5 for every 10 shares.
Renzi Xing: Pushes 8.96 million restricted stock incentive plans
Ren Zixing (300311) announced on the evening of April 15 the draft 208 Restricted Stock Incentive Plan, which proposed to grant 896,000 shares of restricted stock, accounting for 2% of the company’s total share capital at the time of the draft announcement. Among them, 8.14 million shares were granted for the first time, and 820,000 shares were reserved. The total number of incentive objects granted for the first time is 256, including some directors, senior management personnel, middle management personnel, and core business (technical) personnel; the grant price is 6.91 yuan per share; the performance assessment condition is that the 2018 net profit will be no less than 150 million yuan, 2019 net profit of not less than 160 million yuan.
Harbin Pharmaceutical Co., Ltd.'s net profit grew more than twice in the first quarter
Harbin Pharmaceutical Co., Ltd. disclosed a quarterly report. The company's operating income in January and March of 2018 was 2,857,831,646.74 yuan, a year-on-year decrease of -7.38%; the net profit attributable to shareholders of listed companies was 140,227,002.06 yuan, an increase of 201.22% year-on-year; basic earnings per share was 0.06 yuan.
Socket: First-quarter net profit increased more than 4 times year-on-year
Good Bede (300322) disclosed a quarterly report on the evening of April 15. The company achieved total operating revenue of 361 million yuan in the first quarter of this year, an increase of 14.79% year-on-year; net profit of 15.5225 million yuan, an increase of 412.62% year-on-year. In addition, the company's wholly-owned subsidiary, Soude Hong Kong, will co-invest with Chen Dongxu and others to establish Speedlink Technology Inc, a company that holds a 55% stake in the company for US$1.65 million. This investment is conducive to grasping the trend of the electronics industry and opening up the North American market.
*ST New City: 2017 net profit exceeded 100 million yuan
* ST Xincheng (000809) disclosed its annual report and quarterly report on the evening of April 15. The company achieved revenue of 79.7237 million yuan in 2017, an increase of 279.12% year-on-year; net profit of 101 million yuan, turning losses year-on-year, and a net profit loss of 240 million yuan in the previous year; Revenue 0.12 yuan. The net profit turn-over was mainly due to the realization of land sales income during the reporting period, and at the same time, the receivables from previous years were reverted back to the corresponding provisioned bad debts. In the first quarter of this year, the company made a profit of RMB 29,907,600. The company withdrew its accounts receivable, offsetting the corresponding provision for bad debts, resulting in an increase in cash flow and an increase in profits.
Pien Tze Huang Increases Its Net Profit by Over 50% in 2017
Pienze Tsai disclosed its annual report. The company's operating revenue in 2017 was 3,713,953,975.95 yuan, an increase of 60.85% year-on-year; net profit attributable to shareholders of listed companies was 807,018,675.04 yuan, an increase of 50.53% year-on-year; basic earnings per share was 1.34 yuan. Based on the company's total share capital of 603,317,210 shares on December 31, 2017, the company distributed a cash dividend of 4.30 yuan (tax included) for every 10 shares.
Black sesame seeds: sales of black and light light-fat beverages have gradually increased
Black Sesame (000716) today said on the interactive platform that the company’s sales of black and light light fat beverages have gradually increased. The main sales regions are in Guangdong, Fujian, Sichuan, Yunnan, Jiangsu, Anhui and other key markets such as South China, Southwest China and East China.
Five types of taboos: one bogey, two bogey fears, three taboos, four taboos, and five taboos;
Five Conditions: Knowledge, Patience, Courage, Health, and Capital
Crystal Ball this week
Huarong (famous senior professional trader): Northeast Pharmaceutical - performance growth rate; Weixing shares - valuation is not high, the trend is steady.
Weiqi China (well-known investors): Zhongcheng shares - Belt and Road; Honghui Fruits and Vegetables - Agriculture.
Yan Hua (Chairman of Investment Company): Lida shares - Hainan section; Shuangcheng Pharmaceutical - Hainan leader.
Wu Guoping (Privately Private Equity): Ray Media - High Quality Blue Chips; Anyuan Coal Industry - Growth Unit
Dr. Deng's daily tactics (Private Equity Fund Chairman): Tianguang Zhongmao - agriculture; there are new materials - chips.
Liu Yuxin (CEO): Shennong Gene - Free Trade Zone Concept; Yintai Resource - Gold Concept.
Zhan Feng (investment celebrity): HKUST Guochuang - mid-range potential bull stocks; Jianyi Group - change hands cattle stocks early warning.
Yuhui battleship (financial name Bo): China Haida -...